MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
17.17
-0.11
-0.64%
After Hours: 17.25 +0.08 +0.47% 16:51 02/20 EST
OPEN
17.13
PREV CLOSE
17.28
HIGH
17.61
LOW
16.89
VOLUME
861.77K
TURNOVER
0
52 WEEK HIGH
18.85
52 WEEK LOW
4.290
MARKET CAP
1.07B
P/E (TTM)
21.51
1D
5D
1M
3M
1Y
5Y
Macrogenics Inc: Statement of changes in beneficial ownership of securities
Press release · 4h ago
MacroGenics: Evaluating Its Buy Status After A 200% Surge On Prostate Cancer Prospects
MacroGenics' stock has increased by 230% since September due to favorable macroeconomics and interest in antibody-drug conjugates. The company is testing vobramitamab duocarmazine for the treatment of metastatic castration-resistant prostate cancer. MacroGenics has a strong financial position, promising pipeline, and positive market sentiment.
Seeking Alpha · 1d ago
Weekly Report: what happened at MGNX last week (0212-0216)?
Weekly Report · 1d ago
MacroGenics: Trying To Build A Better Everything
MacroGenics, Inc. Has a pipeline of promising drugs. The company's only approved therapy is margetuximab for HER2-positive breast cancer. MGNX faces both strengths and risks in their drug development and commercialization efforts. The share price of the company has more than tripled since November.
Seeking Alpha · 5d ago
Decoding 4 Analyst Evaluations For Macrogenics
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. In the last three months, 4 analysts have published ratings on Macrogenics. The company has an average 12-month price target of $15.0. The average price target has increased by 55.12% in the last year.
Benzinga · 6d ago
HC Wainwright & Co. Downgrades Macrogenics to Neutral, Raises Price Target to $14
Benzinga · 6d ago
Macrogenics Inc: Statement of changes in beneficial ownership of securities
Press release · 02/13 00:09
Weekly Report: what happened at MGNX last week (0205-0209)?
Weekly Report · 02/12 09:05
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Webull offers MacroGenics Inc stock information, including NASDAQ: MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.